JNJ stock forecast, quote, news & analysis

Key Takeaways

• Johnson & Johnson shares closed near $261, roughly 2% lower over the trailing 30 days—a modest move that keeps the stock well within low-volatility, defensive territory.
• The pullback stems mainly from a late-September decline after a court rejected the company's latest talc-bankruptcy plan, partially offset by an early-October rebound.
• Diversified Innovative Medicine and MedTech businesses provide balance, with oncology and immunology products such as Darzalex and Tremfya driving growth.
• J&J has raised its dividend for 64 consecutive years and lifted full-year 2026 guidance past the $100 billion sales milestone.
• Wall Street holds a consensus "Moderate Buy" rating, with recent price targets of $290 from RBC Capital and $294 from Morgan Stanley.

Current Market Snapshot

Johnson & Johnson (JNJ) trades near $261 with a market capitalization around $615 billion and a notably low beta of roughly 0.21, underscoring its profile as a defensive blue chip. The stock's 52-week range spans from about $184.66 to $281.07, placing current levels well above the low but still below the early-September peak. Health care has been one of the quieter corners of the market, lagging the technology-led rally while higher Treasury yields weigh on dividend-paying names. Within this backdrop, JNJ has moved in a relatively narrow band, with brief bouts of selling tied to litigation headlines rather than a deterioration in underlying fundamentals.

Johnson & Johnson (JNJ) Business Overview and Competitive Position

Johnson & Johnson is a global healthcare company organized around two segments. Innovative Medicine develops prescription therapies across immunology, oncology, neuroscience, cardiovascular and metabolic disease, and infectious diseases, and accounts for roughly two-thirds of sales. MedTech supplies surgical, orthopedic, cardiovascular and vision products used by hospitals and clinicians worldwide. After separating its consumer health business, the company has become a more focused enterprise tilted toward higher-growth, innovation-driven categories.

The company's scale, diversified pipeline and strong balance sheet set it apart from peers such as MRK and AMGN. It operates with a large research budget, an extensive global manufacturing network and one of the strongest credit ratings in corporate America. Those attributes support a dividend record that has extended for more than six decades, making JNJ a fixture in income-oriented and defensive portfolios.

Recent Developments Driving JNJ

Second-quarter results, reported in July, exceeded expectations. Revenue rose 6.6% year over year to $25.31 billion, with adjusted EPS of $2.90, as management raised full-year guidance to adjusted operational sales of $100.3 billion to $100.9 billion—the first time the company has guided above $100 billion. Growth was led by oncology products such as Darzalex and immunology names including Tremfya, while MedTech grew more slowly.

The dominant near-term catalyst has been talc litigation. In July, J&J announced a $5.5 billion settlement to resolve ovarian-talc claims. However, in late September a Texas court rejected the company's third attempt to resolve the claims through a bankruptcy filing by subsidiary Red River Talc, prompting a sharp one-day decline of roughly 7.6% as the company signaled a return to the tort system. The episode reinforced the litigation overhang that has periodically pressured the shares.

Elsewhere, J&J reached a drug-pricing agreement with the federal administration exchanging discounted access to select medicines for relief from pharmaceutical import tariffs, reducing a layer of sector-wide uncertainty. The company also presented long-term clinical data for Icotyde in plaque psoriasis and Imaavy in generalized myasthenia gravis, along with encouraging Phase 3 results for a Tecvayli-Talvey combination in multiple myeloma. Analysts have responded constructively, with RBC Capital raising its price target to $290 and Morgan Stanley initiating coverage with a Buy rating and a $294 target. Headwinds remain, including biosimilar erosion of Stelara and a slower MedTech segment.

Trending AI Robots

Tickeron's Trending AI Robots page curates a focused selection of the platform's top-performing and most relevant AI trading bots. While Tickeron offers hundreds of AI-driven bots that trade thousands of tickers across equities, ETFs, forex and cryptocurrencies, only those meeting strict performance and relevance criteria appear in this section. Each bot differs in strategy, holding timeframe and performance metrics, allowing traders to compare approaches that range from short-term momentum to longer-horizon trend following. The curated view helps users identify strategies that are currently resonating with market conditions. Traders seeking data-driven signals alongside their own research may find the section a useful starting point.

2026 Outlook and What Investors Should Watch

Looking ahead, the most immediate catalyst is the company's third-quarter earnings report, expected in mid-October, where investors will focus on sales growth, margin trends and management's outlook. Beyond the quarter, several themes will shape the stock. The pace of Stelara erosion from biosimilar competition will test whether newer oncology and immunology launches can offset lost revenue. Resolution of the talc litigation, whether through settlement or the tort system, remains a key swing factor for sentiment.

Macroeconomic conditions also matter. The path of Treasury yields and interest rates will influence how dividend-paying defensive stocks are valued, while evolving drug-pricing and trade policies could affect net realized prices across the industry. Finally, pipeline execution—including late-stage readouts and regulatory decisions across oncology, immunology and neuroscience—will help determine whether JNJ can sustain the accelerating growth profile it has emphasized in recent quarters. As always, these factors should be weighed as part of a broader, diversified investment approach rather than as standalone signals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations